Date: June 18, 2025
Time: 8:00 AM (PT), 11:00 AM (ET), 5:00 PM (CET)
Discover how Novartis and Genedata partnered in the development of a robust, efficient, and user-friendly New Peak Detection (NPD) workflow to facilitate the implementation of the Multi-Attribute Method (MAM) by Liquid Chromatography Mass Spectrometry (LC-MS) across the global biopharma network, from R&D through regulated environments.
Following a brief introduction to MAM, the webinar covers innovative targeted attribute monitoring as well as NPD workflows using Genedata Expressionist. A key challenge in NPD data analysis is to distinguish true signals from false positives within complex spectra - a task that traditionally requires time-consuming manual review by MS experts. The presentation highlights the innovative NPD functionalities developed in Genedata Expressionist and available to all users in the latest release. These new capabilities address the above challenge by introducing automated processes to detect and reduce false positives, enabling non-MS specialists to perform routine analysis in quality control (QC) settings.
Learn how:
- MAM can replace multiple conventional purity methods while providing improved specificity and supporting structure-function understanding.
- Genedata Expressionist allows for de-bottlenecking the analysis of large sample cohorts by MAM targeted attribute monitoring.
- A harmonized MAM NPD workflow using Genedata Expressionist is expected to facilitate the implementation of MAM across research, development, and QC labs.
Who should attend:
- Biopharma, Biotech, and CRO R&D managers, analytical scientists, and lab heads who are seeking to implement automated MS-based MAM analytics in biotherapeutic R&D through regulated environments.
- Biopharma, Biotech, and CRO organizations looking for an enterprise platform to streamline MS analytics across research, development, and QC labs.
Webinars will be available for unlimited on-demand viewing after live event.